Isomorphic signs discovery collaborations with Eli Lilly and Novartis worth up to about $3B combined

Isomorphic Labs/Drug design engine and pipeline

Isomorphic Labs signed small-molecule discovery collaborations with Eli Lilly ($45M upfront) and Novartis ($37.5M upfront). Together the deals could be worth nearly $3B in milestones, excluding royalties, signalling big pharma's confidence in AI-first drug design.

• Eli Lilly deal: $45M upfront for multi-target small-molecule research.
• Novartis deal: $37.5M upfront for small-molecule therapeutics discovery.
• $3B combined potential value includes milestone payments; royalties on successful drugs are additional.
• Deals validate AlphaFold 3 for structure-based drug design; largest proof-of-concept for AI-designed therapeutics.